U of Miami, Seed-One Launch Heat Biologics To Develop Lung Cancer Vaccine, Asthma Rx | Biotech Transfer Week | Biotechtransferweek | GenomeWeb

The University of Miami Miller School of Medicine and venture capital firm Seed-One Ventures last week said that they have created a startup company called Heat Biologics to further develop a potential lung cancer vaccine and asthma therapy discovered at the school.

The vaccine, based on the heat shock protein gp-96, is intended as a treatment for non-small cell lung cancer patients, for whom current treatment options are essentially limited to surgery or chemotherapy.

Heat Biologics is currently enrolling patients in a Phase I clinical trial of the vaccine at UM’s Sylvester Comprehensive Care Center, and said that it hopes to receive fast-track designation by the US Food and Drug Administration based on the current dearth of treatment options for NSCLC.

Meantime, the asthma therapy, based on agonists and antagonists of tumor necrosis factor receptor 25, is being considered as an adjunct therapy to increase the efficacy of the NSCLC vaccine, but may also have potential as a standalone treatment for asthma and other autoimmune diseases.

Read full article here: U of Miami, Seed-One Launch Heat Biologics To Develop Lung Cancer Vaccine, Asthma Rx | Biotech Transfer Week | Biotechtransferweek | GenomeWeb